A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab

SIMPLE SUMMARY: Pembrolizumab, a monoclonal antibody targeting programmed cell death 1, improves the survival of patients with advanced melanoma. This study aimed to investigate the association of baseline clinical characteristics, laboratory and imaging variables, and gene expression profiling scor...

Descripción completa

Detalles Bibliográficos
Autores principales: Awada, Gil, Jansen, Yanina, Schwarze, Julia Katharina, Tijtgat, Jens, Hellinckx, Lennert, Gondry, Odrade, Vermeulen, Sim, Warren, Sarah, Schats, Kelly, van Dam, Pieter-Jan, Kockx, Mark, Keyaerts, Marleen, Everaert, Hendrik, Seremet, Teofila, Rogiers, Anne, Neyns, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825041/
https://www.ncbi.nlm.nih.gov/pubmed/33418936
http://dx.doi.org/10.3390/cancers13020168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825041/
https://www.ncbi.nlm.nih.gov/pubmed/33418936
http://dx.doi.org/10.3390/cancers13020168

Ejemplares similares